132 results on '"Gramegna, Andrea"'
Search Results
2. Standards for the care of people with cystic fibrosis (CF); Planning for a longer life
3. Standards of care and educational gaps in adult cystic fibrosis units: an ERS survey
4. Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy
5. Diagnostic delay in bronchiectasis: an Italian perspective
6. Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review
7. Covid-19 in cystic fibrosis patients compared to the general population: Severity and virus-host cell interactions
8. Post-COVID-19 sequelae
9. Respiratory failure in COVID-19: a patient's perspective and clinical cases
10. Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor–tezacaftor–ivacaftor combination: a 1-year observational study
11. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues
12. The impact of elexacaftor/tezacaftor/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: An expert-based Delphi consensus
13. Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments
14. Standards for the care of people with cystic fibrosis; establishing and maintaining health
15. Idiopathic interstitial pneumonia in a patient with Von Hippel-Lindau syndrome: a first case
16. Monitoring of ECFS quality standards for the clinical management of adults with cystic fibrosis
17. Walking the path of treatable traits in interstitial lung diseases
18. Severity of SARS-CoV-2 infection in a hospital population: a clinical comparison across age groups
19. Standards for the care of people with cystic fibrosis (CF)
20. Lung volumes as possible factors explaining the heterogeneity in the response to elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease
21. Bronchiectasis and cardiovascular risk: a systematic review and meta-analysis
22. The Successful Procedures Of weaning from Tracheostomy (SPOT) study: preliminary analysis of predictive factors for failure and validation of the QsQ score
23. Bronchiectasis associated to connective tissue diseases: a single-center experience
24. Single cells RNA sequencing of peripheral blood mononuclear cells reveals that hyperinflammatory monocytes are associated with the risk of Mycobaterium abscessus pulmonary disease
25. Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?
26. Standards for the care of people with cystic fibrosis (CF): A timely and accurate diagnosis
27. Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
28. Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
29. Hospital-acquired pneumonia
30. Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia
31. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
32. Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis
33. Comments on “PD-1 Inhibitor for Disseminated Mycobacterium avium Infection in a Person Living With HIV”
34. Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging
35. Treatable traits in interstitial lung diseases: a call to action
36. Microbial Inflammatory Networks in Bronchiectasis Exacerbators With Pseudomonas aeruginosa
37. Single Cells RNA Sequencing Reveals that Circulating Hyperinflammatory Monocytes are Associated with Mycobacterium abscessus Pulmonary Disease
38. Alpha1-Antitrypsin Inherited Variants in Patients With Bronchiectasis
39. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis
40. Pro-resolving and pro-inflammatory fatty acid-derived mediators in sputum of stable state bronchiectasis patients
41. Genetic and Serum Screening for Alpha-1-Antitrypsin Deficiency in Adult Patients with Cystic Fibrosis: A Single-Center Experience
42. Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study
43. Respiratory viruses in stable bronchiectasis: A multicenter evaluation in Northern Italy
44. Hesitancy toward the Full COVID-19 Vaccination among Kidney, Liver and Lung Transplant Recipients in Italy
45. Pro-resolving and pro-inflammatory fatty acid-derived mediators in sputum of stable state bronchiectasis patients
46. Impact of COVID-19 on Lung Disease in People with Cystic Fibrosis: A 6-Month Follow-Up Study on Respiratory Outcomes
47. Heterogeneity of weight gain after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis
48. Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis
49. Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review
50. Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.